Intelligence-Based Medicine · 2025 · 14 citations · 33 references
ComputingBiomedical InformaticsData ScienceDementiaMachine LearningPredictive AnalyticsDecision TreesDementia DiagnosisEnsemble LearningEnsemble MethodsExplainable Machine LearningFeature SelectionAlzheimer's Disease DiagnosisClass Imbalance LearningExplainable Artificial IntelligenceFeature Selection In DiagnosisGradient BoostingHandling Missing Clinical DataMachine Learning For DiagnosisMachine Learning Prediction Models
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that necessitates early and accurate diagnosis for effective intervention. This study presents a novel machine learning (ML)-driven predictive framework for AD diagnosis, integrating Explainable Artificial Intelligence (XAI) methodologies to enhance interpretability. The dataset, sourced from Kaggle, comprises 2149 patient records with 34 distinct attributes, representing a comprehensive range of demographic, clinical, and lifestyle-related factors. To improve model robustness, rigorous data preprocessing techniques were employed, including mean/mode imputation for missing values, feature scaling using min-max normalization, and class balancing via SMOTE, SMOTEENN, and ADASYN. Feature selection technique was performed using Chi-Square and Recursive Feature Elimination (RFE) to retain the most relevant predictors. Various ML models—including Naïve Bayes, Decision Tree, Random Forest, Logistic Regression, AdaBoost, XGBoost, K-Nearest Neighbors (KNN), and Gradient Boosting—were assessed using accuracy, precision, recall, F1-score, and AUC (Area Under the Curve). The proposed ensemble model, combining LightGBM (LGBM) and Random Forest (RF) with Chi-Square feature selection and utilizing soft voting, achieved the highest test accuracy of 96.35 %, surpassing existing models. Additionally, SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) were utilized to interpret the model's decision-making process, identifying key risk factors and improving transparency for clinical applications. These findings highlight the potential of ML and XAI in advancing AD diagnosis, with future work aiming to validate the model on larger, more diverse datasets and integrate it into real-world clinical workflows. • Handled missing values, outliers, and class imbalance to improve data quality through preprocessing • Utilized Chi-square and RFE for feature selection to boost model performance • Applied SHAP and LIME to improve model transparency and highlight key features. • Highlighted ML and XAI’s role in advancing AD diagnosis and aiding clinical decisions
33
Donanemab in Early Symptomatic Alzheimer Disease
John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.6K citations · Full text
Medicine, Neurology, Neuroscience +17
Malti Bansal, Apoorva Goyal, Apoorva Choudhary · Decision Analytics Journal · 2022 · 734 citations · Full text